TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Virtual Audits: To be, or not to be, that is the question

Virtual Audits: To be, or not to be, that is the question

Governments across the globe are starting to re-open, Society and people are returning to their workplaces.  So, what does this mean for the future of virtual audits?  Were they a phenomenon of the pandemic or did the pandemic teach us that by developing technology enabled solutions to complement the technical skillset of our employees, it is possible that virtual audits can continue to provide a real alternative to on-site audits?

An interesting conundrum given the emphasis that is being put on sustainability, reducing carbon footprint and employees ‘new norm’ of operating in a virtual environment.

 

Let’s investigate…..

As we know, it is imperative for companies to engage in proactive auditing to ensure their supply cain management is in a constant state of compliance and is sufficiently robust to be able to manage unforeseen circumstances.  It is incumbent upon companies to ensure their suppliers and contracted organisations continue to supply goods and services that are fit for purpose, meet the required GxP standard and to maintain the terms of quality and technical agreements.

 

So, what are the key questions to be considered to determine whether to conduct a virtual or on-site audit?

 

Risk Management Plan

Pharmaceutical companies can improve the success of both virtual and on-site audits by developing a well-considered risk management plan and strategy for both virtual and on-site audits.

 

Firstly, create a risk management plan which scopes out your entire supply change.  Once the risk assessment determines the requirement to carry out an audit,  the next step is to determine the most appropriate type of audit: on-Site or virtual.

Once the audit is completed, consideration should be given to the next audit required and the type selected. There may be cases where the audit findings may indicate that an onsite audit should be completed the next time. This may be due to expressions of concern or due to difficulty assessing a particular area by virtual means.

The risk assessment should also be updated with information on quality considerations such as quality defects, customer complaints as they arise. This information may change the audit type selected. This risk management plan should be updated accordingly and reviewed periodically to ensure an accurate assessment remains.

In addition to standard considerations when conducting an on-site audit, when considering virtual auditing, the following considerations will help determine the success of your Virtual Audit Programme:

ICT:

How robust is the Auditee’s ICT?  Does it allow for the transfer of data guaranteeing reliable information security and protection of confidentiality?  How adequate is the Wi-Fi or broadband access to allow for a smooth auditing process?

 

Has the Auditee an eQMS Document Management System or do they operate a paperbased QMS?  Some smaller suppliers may not have the capital available to invest in an eQMS Document Management System. If paper-based, what steps would be required to assist the Auditee to transfer this information through a safe cloud solution?

 

The Auditor

How proficient is the Auditor in the use of ICT?  Do they have access to a suitable remote work environment that minimizes interruptions, noise, and other distractions?

 

Quality of Objective Evidence

As we have previous outlined in our recent Virtual Audit Whitepaper, another challenge is ensuring the quality of objective evidence.  As we know, the purpose of conducting an audit is to evaluate the adequacy of the supplier’s operation and their compliance with GxP requirements.  For this assessment to be comprehensive and to stand up to regulatory scrutiny, the ability to gather sufficient objective evidence is of paramount importance.

 

Setting your Virtual Audit up for success:

To help companies to implement successful virtual audits, we recommend consideration of the following to allow for effective sharing of such evidence with auditors whilst maintaining security and confidentiality:

  • Can the audit include real-time images?
  • Can interviews and feedback be recorded?
  • How can the company ensure that the auditor receives an objective and thorough view of the facility, equipment, operations, and controls?
  • How can the company provide access to relevant information without compromising privacy or confidentiality?
  • What type of file sharing is appropriate, and what access levels are needed?
  • Is the company’s cloud storage plan sufficient for document transfer?
  • Which documents can be viewed via camera or online, and which need to be delivered via courier?

Resolving these challenges is a key part of planning an effective virtual audit.

To help pharmaceutical companies implement successful remote audits, PharmaLex has developed a virtual auditing model that combines these elements into an efficient 5-stage workflow, as illustrated in Figure 1.

Virtual Audits to Remain

Even though virtual audits became a necessity during the covid-19 pandemic, most pharmaceutical companies now realise they are an integral way of making an assessment of a potential or current outsourced activity provider. It is however important to remember to use them in conjunction with robust justification, always ensuring adequate assessment is completed and switching to onsite audits in higher risk situations.

 

If you require any assistance with keeping your audit program on track, please do not hesitate to contact us here

Related posts
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Quality Risk Management ICH Q9 – Revision published for public comments
Quality Risk Management ICH Q9 – Revision published for public comments
5th January 2022
Points de vigilance vis-à-vis de la communication institutionnelle en France
Points de vigilance vis-à-vis de la communication institutionnelle en France
23rd November 2021
Search
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
20 May

PharmaLex is excited to be supporting the #ARCSannualconference again this year. Be sure to join their sessions and visit our team at stand 44.

Find out more: https://lnkd.in/g6fbC2kr

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • They are available when we need to talk to them despite any time zone differentials

    Japan based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for